Humira (adalimumab) is a fully human monoclonal antibody targeting TNF-α. It was the world’s best-selling drug for over a decade, reaching peak sales of $21B+ before US biosimilar launch in 2023.
Humira binds to TNF-α, a central inflammatory mediator, blocking it from activating TNF receptors. This reduces inflammation, immune cell activation, and tissue destruction in autoimmune diseases.
Annual revenue trajectory
Revenue of competing drugs in the same class
8 indications
All approved therapeutic uses
Humira maintained monopoly status for over a decade. US biosimilar launch in Jan 2023 began rapid market erosion. AbbVie is transitioning patients to Skyrizi and Rinvoq.
Revenue expected to decline to $8-10B by 2026 as biosimilar penetration accelerates. AbbVie’s Skyrizi + Rinvoq generated $12B+ in 2023 as successor franchise.
| Drug | Company | Revenue |
|---|---|---|
| Amjevita (adalimumab-atto) | Amgen | $1.2B |
| Hyrimoz (adalimumab) | Sandoz/Novartis | $0.8B |
| Stelara (ustekinumab) | J&J | $9.8B |
| Skyrizi (risankizumab) | AbbVie | $7.7B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.